Get Live Data

The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News
  5. PDMR Notification & Director Shareholding

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Notification & Director Shareholding

2 Nov 2023 18:20

Arix Bioscience PLC (ARIX) PDMR Notification & Director Shareholding 02-Nov-2023 / 18:20 GMT/BST

Arix Bioscience plc("Company")

PDMR Notification & Director Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 60,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 2nd November 2023 at a price of £1.1469 per share.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

 Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

c)

Price(s) and volume(s)

 

Price(s)£

Volume(s)

 

 

 

1.1469

60,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

60,000

- Price

£68,815.20

e)

 

Date of the transaction

 

2 November 2023

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact: Kin Company Secretarial Limited, Company Secretary+44 20 8819 6486

Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:DSH
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:282417
EQS News ID:1764141
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

3456789101112
Date   Source Headline
21st Feb 20187:00 amRNSArix Bioscience and Ipsen sign strategic agreement
19th Feb 20187:00 amRNSArix signs strategic agreement with Fosun
4th Jan 20182:00 pmRNSCEO Letter to Shareholders
3rd Jan 20189:46 amRNSVoting Rights and Capital: Month End Disclosure
22nd Dec 20177:00 amRNSIssue of Ordinary Shares, TVR, PDMR Shareholding
21st Dec 20177:00 amRNSArix co-leads $30m financing for Aura Biosciences
4th Dec 20177:00 amRNSArix Bioscience leads $30m financing for Atox Bio
10th Nov 20179:00 amRNSSir John Banham retires from Board of Directors
1st Nov 20177:00 amRNSArix to present at two IR conferences
18th Oct 20171:31 pmRNSArix notes Harpoon AbbVie IO collaboration
17th Oct 20177:10 amRNSDirector Declaration
17th Oct 20177:00 amRNSGiles Kerr Appointed to Board of Directors
10th Oct 20177:00 amRNSArix Bioscience notes positive data from Amplyx
26th Sep 20177:00 amRNSArix participates in $80 million Autolus financing
18th Sep 20177:20 amRNSClinical progress from Autolus
18th Sep 20177:00 amRNSCapital Markets Meeting Today
14th Sep 20177:00 amRNSArix Bioscience Capital Markets Meeting
8th Sep 20174:27 pmRNSArix to present at Rodman & Renshaw conference
7th Sep 20172:00 pmRNSArix notes positive Verona data in COPD
4th Sep 20177:05 amRNSArix Bioscience notes Artios CSO Appointment
2nd Aug 20177:00 amRNSArix participates in $67m financing for Amplyx
31st Jul 20177:00 amRNSReport for the Six Months Ended 30 June 2017
27th Jul 20177:00 amRNSArix Bioscience: $29M Series A for PreciThera
21st Jul 20173:17 pmRNSMeghan FitzGerald appointed to Board of Directors
17th Jul 20177:00 amRNSNotice of Results
10th Jul 20177:00 amRNSArix Bioscience plc Appoints General Counsel
28th Jun 20177:00 amRNSArix Bioscience leads $45M financing round
27th Jun 201712:00 pmRNSArix Bioscience in $20M Mitoconix Bio fundraise
12th Jun 20177:01 amRNSArix notes Artios collaboration
5th Jun 20173:45 pmRNSResult of AGM
5th Jun 20177:00 amRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSArix to present at Jefferies Healthcare Conference
30th May 20177:00 amRNSDirector/PDMR Shareholding
30th May 20177:00 amRNSAppointment of Jefferies and Stifel as brokers
26th May 20174:35 pmRNSPrice Monitoring Extension
25th May 20177:00 amRNSArix Bioscience Leads Harpoon Therapeutics Round
19th May 20177:00 amRNSArix leads $65m Series B investment for Iterum
9th May 20177:00 amRNSDirector share purchases
28th Apr 201712:04 pmRNSArix Notes Verona's NASDAQ Listing
28th Apr 20178:00 amRNSAnnual Financial Report
18th Apr 201712:00 pmRNSGroup business Verona receives IND for RPL554
31st Mar 20177:00 amRNSBoard Committee Changes
22nd Mar 20172:52 pmRNSHolding(s) in Company
20th Mar 20177:05 amRNSArix Bioscience, LDC, Leeds University Agreement
20th Mar 20177:02 amRNSPartial Exercise of Over-Allotment Option
20th Mar 20177:01 amRNSEnd of Stabilisation Notice
20th Mar 20177:00 amRNSMid-Stabilisation Period Announcement
10th Mar 20174:30 pmRNSMid-Stabilisation Period Announcement
10th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20177:00 amRNSHolding(s) in Company
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.